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Abstract  
Aims: The main objective of the present work was to evaluate the capacity of wild 
mushroom extracts to potentiate the action of standard antibiotics, through synergisms 
that allow a decrease in their therapeutic doses and ultimately contribute to the 
reduction of resistances.  
Methods and Results: Wild mushroom extracts were applied to different multi-
resistant microorganisms (Escherichia coli, Extended-spectrum beta-lactamase-
producing (ESBL) Escherichia coli and Methicillin-resistant Staphylococcus aureus 
(MRSA), combined with commercial antibiotics (Penicillin, Ampicillin, 
Amoxicillin/Clavulanic acid, Cefoxitin, Ciprofloxacin, Cotrimoxazol, Levofloxacin). 
Microdilution method was used to determine minimum inhibitory concentrations 
(MICs). The results obtained showed higher synergistic effects against MRSA than 
against E. coli. Mycena rosea and Fistulina hepatica were the best extracts for 
synergistic effects against MRSA. The efficiency of Russula delica extract against E. 
coli 1 (resistant to Ampicillin, Ciprofloxacin and Trimethoprim/Sulfasoxazole) and E. 
coli 2 (resistant to Amoxicillin/Clavulanic acid and Ampicillin) was higher than that of 
Leucopaxillus giganteus extract; nevertheless the latter extract exhibited better 
synergistic effects against ESBL E. coli.  
Conclusions: This study shows that, similarly to plants, some mushroom extracts can 
potentiate the action of antibiotics extensively used in clinical practice for Gram-
positive or Gram-negative bacteria, with positive action even against multi-resistant 
bacteria. 
Significance and Impact of the Study:	  Mushroom extracts could decrease therapeutic 
doses of standard antibiotics and reduce microorganism’s resistance to those drugs. 
Keywords: Antibiotics; Wild mushroom extracts; Synergism; Multi-resistant bacteria
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Introduction 
The indiscriminate use of antibiotics and chemotherapeutic agents, among other factors, 
has been contributing for the development of resistant species (Andrade et al. 2006). 
For patients, antimicrobial resistance increases morbidity and mortality, while there is a 
significant increase in costs for health care institutions. Because of that, a huge effort 
has been directed towards controlling antibiotic use and raising public awareness of the 
need for prudent use of antibiotics (Dancer 2001; Coutinho et al. 2005) and finding new 
sources of active molecules.  
In general, bacteria serve as host for multiple genetic elements like genes, integrons, 
transposons and plasmids that confer antibiotic resistance phenotypes. So, they have the 
genetic ability to transmit and acquire resistance to drugs that are used as therapeutic 
agents (Santos et al. 2011). 
Bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and Extended-
spectrum β-lactamase (ESBL)-producing Escherichia coli are microorganisms of 
concern with regard to multi-resistances (Calbo et al. 2006; Donskey 2006; Chambers 
and Deleo 2009). Due to this problem, there is a need to investigate new compounds or 
strategies to reverse this tendency in order to achieve the appropriate and effective 
treatment against infections by such microorganisms. 
Natural matrices, in particular wild mushroom extracts emerge as interesting 
possibilities to be explored as antimicrobial drugs (Alves et al. 2012a). Mushrooms are 
rich sources of natural antimicrobials, as they produce antibacterial and antifungal 
compounds to survive in their natural environment (Rathee et al. 2012).    
Additionally, it has been reported that the exposure of some food pathogens to 
increasing sublethal amounts of natural antimicrobials resulted in no significant global 
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effects on the acquisition of direct tolerance, namely by L. monocytogenes, which 
maybe an additional advantage when compared to standard antibiotics (Luz et al. 2012).  
In the last few years, a number of studies have been conducted in different countries to 
demonstrate the efficacy of natural products, not only studying their direct antimicrobial 
activity but also their capacity as resistance-modifying agents (Benoit-Vical et al. 2006; 
Singh et al. 2007). The resistance modification is based on creating a synergistic 
relationship, i.e. a positive interaction created when two combined agents exert an 
inhibitory effect that is greater than the sum of their individual effects (Aiyegoro and 
Okoh 2009). It has been proven that, in addition to production of intrinsic antimicrobial 
compounds, plants also produce multi-drug resistance inhibitors, which enhance the 
activity of the antimicrobial compounds (Stermitz et al. 2000). 
According to Wagner and Ulrich-Merzenich (2009), natural extracts can provide a 
synergistic relationship with antibiotics, through a multi-or single-target action.  A 
“Synergistic multi-target effect” means that the single constituents of a mono-extract or 
a multi-extract combination affect not only one single target, but several targets, and 
therefore cooperate in an agonistic, synergistic way. On the other hand, the extracts can 
display a mono-target action that results from the interaction of the extract with one 
single target. Several other authors support the mentioned idea reporting studies of 
synergism between natural products and antibiotics (Coutinho et al. 2008; Hemaiswarya 
et al. 2008; Aiyegoro and Okoh 2009; Coutinho et al. 2009; Palaniappan and Holley 
2010; Braga et al. 2011; Santos et al. 2011; Mitchell et al. 2012). 
The understanding of the molecular mechanisms of synergy would tackle a new strategy 
for the treatment of infectious diseases, overcome drug-resistant pathogens, and reduce 
the use of antibiotics and consequently the side effects created by them (Hemaiswarya 
et al. 2008). 
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Taking into account our previous results highlighting the antibacterial activity of 
extracts from specific wild mushrooms (Fistulina hepatica, Leucopaxillus giganteus, 
Mycena rosea, Russula delica, Sarcodon imbricatum) (Alves et al. 2012b), those 
extracts were applied to different multi-resistant microorganisms (Escherichia coli, 
Extended-spectrum beta-lactamase-producing (ESBL) Escherichia coli and Methicillin-
resistant Staphylococcus aureus (MRSA), combined with commercial antibiotics 
(Penicillin, Ampicillin, Amoxicillin/Clavulanic acid, Cefoxitin, Ciprofloxacin, 
Cotrimoxazol, Levofloxacin). The main objective was to evaluate the capacity of 
natural extracts to potentiate the action of standard antibiotics, through synergisms that 
allow a decrease in their therapeutic doses and a protection against increasing 
resistance. Furthermore, this is an important study since the available reports on 
literature are mainly related with plants and not with mushroom extracts.     
 
Materials and methods 
Mushroom species and extracts preparation 
Five mushroom species (Fistulina hepatica, Leucopaxillus giganteus, Mycena rosea, 
Russula delica, Sarcodon imbricatum) were collected in different ecosystems of the 
Trás-os-Montes region in the northeast of Portugal according to the information 
provided in Alves et al. (2012b). Representative voucher specimens were deposited at 
the herbarium of Escola Superior Agrária of Instituto Politécnico de Bragança. After 
taxonomic identification, the mushrooms were immediately lyophilized (Ly-8-FM-
ULE, Snijders, the Netherlands) and kept in the dark in hermetically sealed plastic bags 
up to the point of analysis. 
Each mushroom lyophilized sample (3 g) was extracted using a methanol/water (80:20; 
30 mL) mixture at 20 °C for 6 h. After 15 min in an ultrasonic bath, the extract was 
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centrifuged at 4000 g for 10 min and filtered through Whatman no. 4 paper. The residue 
was then extracted with two additional 30 mL portions of the methanol/water mixture. 
The combined extracts were evaporated at 40 °C under reduced pressure to remove 
methanol (rotary evaporator Büchi R-210, Flawil, Switzerland), lyophilized, redissolved 
in water, at a defined concentration and stored at 20 °C for further use. 
 
Antibiotics 
The antibiotics were selected according to the resistance profile of the studied bacteria: 
Penicillin, Ampicillin, Amoxicillin/Clavulanic acid, Cefoxitin, Ciprofloxacin, 
Cotrimoxazol, Levofloxacin and were used as antibiotic (Sigma-Aldrich, St Quentin 
Fallavier, France).  
 
Microorganisms  
The microorganisms used were clinical isolates from patients hospitalized in various 
departments of the Hospital Center of Trás-os-Montes and Alto Douro – Chaves, 
Portugal.  One Gram-positive bacteria, MRSA (resistant to beta-lactams − Penicillin 
Ampicillin, Cefoxitin, but also to Quinolones − Ciprofloxacin and Levofloxacin) 
isolated from wound exudates; and three Gram-negative bacteria with different 
antibiotic resistance profile: E. coli 1 (resistant to Ampicillin, Ciprofloxacin and 
Trimethoprim/ Sulfamethoxazole), E. coli 2 (resistant to Amoxicillin/Clavulanic acid 
and Ampicillin) and E. coli ESBL (resistant to Ampicillin, Nalidixic acid, Norfloxacin,  
Ciprofloxacin,  Cephalosporins and Trimethoprim/Sulfamethoxazole) isolated from 
urine, were used to screen the antimicrobial activity of the mushroom extracts and 
antibiotics. All strains were identified using the MicroScan® panels automated 
methodology – Siemens (Camberley, UK).  
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Bacterial susceptibility determinations 
MIC determinations were performed by the microdilution method and the rapid INT (p-
iodonitrotetrazolium chloride) colorimetric assay following the methodology previously 
described by the authors (Alves et al. 2012b). Initially, four dilutions were made with 
each mushroom extract and antibiotic in MHB (Mueller Hinton broth obtained from 
Biomerieux, Marcy l’Etoile, France), with a final concentration equivalent to their 
MICs: 20 mg/mL for extracts, previously reported in Alves et al. (2012b) and the 
concentrations stated in Tables 1 and 2 for antibiotics. 
Each antibiotic was tested individually or in combination with the mushroom extract in 
two different percentages: 40% of antibiotic (20 µL of antibiotic + 30 µL of extract) and 
60% of antibiotic (30 µL of antibiotic + 20 µL of extract). 
Dilutions were carried out over the wells containing 450 µL of MHB and afterwards, 10 
µL of inoculum (1×108 CFU/mL) was added to all the wells. One negative (only with 
MHB) and one positive (with MHB and the inoculum) control were performed. The 
plates were incubated at 37 °C, for 24 h, in an oven (Jouan, Berlin, Germany). The 
MICs of the samples were visualized following the addition of INT dye (Sigma-Aldrich, 
St Louis, MO, USA) (0.2 mg/mL, 40 µL) and incubation at 37 °C for 30 min. Viable 
microorganisms reduced the yellow dye to a pink color. MIC was defined as the lowest 
sample concentration that prevented the color change of the medium and exhibited an 
inhibition of microbial growth. Fractional inhibitory concentration (FIC) was calculated 
according to the equation:  
MICantibiotic+extract/MICantibiotic). The interpretations were made as follows: synergistic (S; 
<0.5), indifferent (I; 0.5 to 4), or antagonistic (A; >4) (Fankam et al. 2011). All the 
assays were carried out in duplicate. 
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Results  
Taking into account our previous findings related to antibacterial activity of wild 
mushrooms (Alves et al. 2012b), the extracts that showed higher activity were selected 
to evaluate possible synergistic effects with different antibiotics. Fistulina hepatica 
(MIC=10 mg/mL), Russula delica (MIC=10 mg/mL), Mycena rosea (MIC=20 mg/mL) 
and Sarcodon imbricatum (MIC=20 mg/mL) extract gave the highest antimicrobial 
activity against MRSA, while Fistulina hepatica, Leucopaxillus giganteus and Russula 
delica extracts (MICs=20 mg/mL) were the best ones against E. coli (Alves et al. 
2012b).	  It should be stated that	  Mycena rosea and Sarcodon imbricatum extracts (up to 
20 mg/mL) did not show activity against E. coli, while Leucopaxillus giganteus (up to 
the same concentration) did not show antibacterial activity for MRSA. 
The results obtained showed higher synergistic effects between mushroom extracts and 
standard antibiotics for MRSA (Table 1) than for E. coli (Tables 2-4). 
Regarding MRSA (Table 1), Mycena rosea and Fistulina hepatica were the best 
extracts for synergistic effects. Both extracts gave synergisms with β-lactamic 
antibiotics (penicillin, ampicillin and cefoxitin). The combination of Mycena rosea with 
cefoxitin 40% revealed the lowest FIC value (0.05; highest synergism), followed by its 
combination with penicillin at the same percentage (FIC=0.1). 
Mycena rosea and Fistulina hepatica extracts also allowed synergistic effects with 
quinolones (ciprofloxacin and levofloxacin) (Table 1).  
It can be observed in all the extracts, an increase of FIC values with the increase of 
antibiotic percentage, occurring in some cases an increase of FIC higher than 0.5, and 
disappearing the synergistic effect.  
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Nevertheless, for Fistulina hepatica extract, despite the increase of FIC values with 
higher antibiotic percentage, the synergism still remains (Table 1). Sarcadon 
imbricatum extract gave the worst results and did not show synergisms with the tested 
antibiotics, except for levofloxacin (Table 1).   
Three E. coli strains with different antibiotics resistance profiles were also studied; one 
of them was extended-spectrum beta-lactamase-producing (ESBL).  
The efficiency of Russula delica extract against E. coli (Tables 2 and 3) was higher 
than Leucopaxillus giganteus extract; nevertheless the latter extract showed better 
synergistic effects against ESBL E. coli (Table 4). Therefore, studies should be carried 
out in order to clarify if Leucopaxillus giganteus inhibits β-lactamases production or 
may act as a beta-lactamase inhibitory compound. Among the three mushroom species, 
Fistulina hepatica extract gave the lowest synergistic effect against E. coli (Tables 2 
and 3). 
The action of ciprofloxacin (quinolone) was potentiated by Russula delica or 
Leucopaxillus giganteus extracts (Tables 3 and 4).  
Russula delica extract was the only one that gave synergistic effects with the 
antimetabolic antibiotic trimethoprim/sulfamethoxazole (Tables 3 and 4).	  As far as we 
know, this is the first study reporting synergism between natural matrices and the 
mentioned antibiotic.  
 
Discussion 
The fight against multi-resistant bacteria is a worldwide problem of public health that 
should be considered in several aspects. The knowledge about the processes related to 
antibiotics action and resistance development, the synthesis and pharmacological 
evaluation of new and more potent antimicrobial agents, their subsequent therapeutic 
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application in a rational way, and the adoption of procedures to control hospital 
infections, represent different levels of continuous and interlinked actions (Silveira et al. 
2005). Furthermore, the new research strategies on antimicrobial natural products 
involving unexplored matrices and the use of genomic tools to increase their production, 
might accelerate the discovery of new antibiotics, overcoming the rapid development of 
bacteria resistance to the available therapeutic agents (Guimarães et al. 2010). 
Several successful studies have been carried out in order to find new natural or synthetic 
products with antimicrobial activity and lower toxicity for hosts (Anaisse 1992; 
Edwards and Filler 1992; Graybill 1992; Guimarães et al. 2010).  
Fistulina hepatica, Leucopaxillus giganteus, Mycena rosea, Russula delica and 
Sarcodon imbricatum extracts are good examples (Alves et al. 2012b) and, in the 
present study, they were applied to different multi-resistant microorganisms 
(Escherichia coli, Extended-spectrum beta-lactamase-producing (ESBL) Escherichia 
coli and Methicillin-resistant Staphylococcus aureus (MRSA), combined with 
commercial antibiotics (Penicillin, Ampicillin, Amoxicillin/Clavulanic acid, Cefoxitin, 
Ciprofloxacin, Cotrimoxazol, Levofloxacin).  
The results obtained showed higher synergistic effects against MRSA than against E. 
coli. Mycena rosea and Fistulina hepatica were the best extracts for synergistic effects 
against MRSA (methicillin-resistant Staphylococcus aureus). The synergistic effects 
against MRSA were observed for some β-lactamics (penicillin, ampicillin and cefoxitin) 
and for two quinolones (ciprofloxacin and levofloxacin). Liu et al. (2000) also reported 
synergism against MRSA of a combination between baicalin, a natural compound from 
Soutellaria amoena, and β-lactamic antibiotics such as ampicillin. The mentioned 
compound increased β-lactamics efficiency through inhibition of β-lactamases 
production. In other study, Zhao et al. (2001) concluded that combination of ECG 
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(epigallocatechin gallate), from Camellia sinensis, with ampicillin also lead to 
synergisms against MRSA, related to a similar interaction with peptidoglycan, in which 
β-lactamics normally act. Braga et al. (2011) described synergism against MRSA due to 
a combination of pomegranate extract and ciprofloxacin, which blocked the efflux 
bombs. Other authors (Bazzaz et al. 2008; An et al. 2011) also reported synergistic 
effects of plant extracts and quinolones (ciprofloxacin and levofloxacin) against MRSA.   
The efficiency of Russula delica extract against E. coli 1 (resistant to Ampicillin, 
Ciprofloxacin and Trimethoprim/Sulfasoxazole) and E. coli 2 (resistant to 
Amoxicillin/Clavulanic acid and Ampicillin) was higher than that of Leucopaxillus 
giganteus extract; nevertheless the latter extract exhibited better synergistic effects 
against ESBL (extended-spectrum beta-lactamase-producing) E. coli. Darwish and 
Aburjai  (2010) also described that two plants, Anagyris foetidae and Lepidium sativum, 
had antagonistic effect upon amoxicillin activity against a standard E. coli strain 
(without resistances), but conducting to synergistic effects against ESBL E. coli. 
As is in the present study in which ciprofloxacin was potentiated by Leucopaxillus 
giganteus and  Russula delica extracts,	   Natarajan et al. (2008) showed synergisms 
between Humulus lupulus extract and ciprofloxacin against E. coli, suggesting the 
modification of membrane permeability as possible mechanism of action. 
The number of available studies regarding synergisms between natural products and β-
lactamics seems to be much lower than other antibiotics (Coutinho et al. 2008; 
Coutinho et al. 2009; D’Arrigo et al. 2010; Braga et al. 2011; Sousa et al. 2013).  
Overall, similarly to plants, some mushroom extracts can potentiate the action of 
antibiotics extensively used in clinical practice for Gram-positive or Gram-negative 
bacteria, and might be used against multi-resistant bacteria. 
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This is a pioneer study regarding synergistic effects between mushroom extracts and 
antibiotics that could allow a decrease in the therapeutic doses and a protection against 
increasing microorganism’s resistance. Nevertheless, more studies should be conducted 
in order to clarify the mechanisms of action that support the observed effects upon each 
antibiotic and microorganism.  
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Table 1. Effect of antibiotics individually and in combination with different mushroom extracts in MRSA (Methicillin-resistant Staphylococcus 
aureus). 
MIC- Minimal inhibitory concentration (µg/mL); FIC- Fractional inhibitory concentration; (S)- Synergism; (I)- Indifference; nt- not tested 
  
Antibiotic Antibiotic 100% 
MIC 
Antibiotic 60% with F. hepatica  
MIC/FIC (Effect) 
Antibiotic 40% with F. hepatica 
MIC/FIC (Effect) 
  Antibiotic 60% with M. rosea 
MIC/FIC (Effect) 
  Antibiotic 40% with M. rosea  
MIC/FIC (Effect) 
Ampicillin 8 2.4/0.3 (S) 1.6/0.2 (S) 2.4/0.3 (S) 1.6/0.2 (S) 
Cefoxitin 4 1.2/0.3 (S) 0.8/0.2 (S) 0.6/0.15 (S) 0.2/0.05 (S) 
Ciprofloxacin 2 0.6/0.3 (S) 0.4/0.2 (S) 0.6/0.3 (S) 0.4/0.2 (S) 
Levofloxacin 4 1.2/0.3 (S) 0.8/0.2 (S) 2.4/0.6 (I) 0.8/0.2 (S) 
Penincillin 8 2.4/0.3 (S) 1.6/0.2 (S) 2.4/0.3 (S) 0.8/0.1 (S) 
Antibiotic Antibiotic 100% 
MIC 
Antibiotic 60% with R. delica  
 MIC/FIC (Effect) 
Antibiotic 40% with R. delica  
MIC/FIC (Effect) 
  Antibiotic 60% with S. imbricatum   
MIC/FIC (Effect) 
  Antibiotic 40% with S. imbricatum   
MIC/FIC (Effect) 
Ampicillin 8 4.8/0.6 (I) 3.2/0.4 (S) >4.8 >3.2 
Cefoxitin 4 1.2/0.3 (S) 0.4/0.1 (S) nt nt 
Ciprofloxacin 2 >1.2 >0.8 >1.2 >0.8 
Levofloxacin 4 1.2/0.3 (S) 0.8/0.2 (S) 0.6/0.15 (S) 0.4/0.1 (S) 
Penincillin 8 4.8/0.6 (I) 1.6/0.2 (S) >4.8 >3.2 
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Table 2. Effect of antibiotics individually and in combination with different mushroom extracts in Escherichia coli 1. 
MIC- Minimal inhibitory concentration (µg/mL); FIC- Fractional inhibitory concentration; (S)- Synergism; (I)- Indifference; nt- not tested 
 
  
Antibiotic 
Antibiotic 100% 
MIC 
Antibiotic 60% with F. 
hepatica  MIC/FIC 
(Effect) 
Antibiotic 40% with F. 
hepatica MIC/FIC 
(Effect) 
  Antibiotic 60% with L. 
giganteus 
MIC/FIC (Effect) 
  Antibiotic 40% with  L. 
giganteus 
MIC/FIC (Effect) 
Ampicillin 16 9.6/0.6 (I) 6.4/0.4 (S) 4.8/0.3 (S) 0.8/0.05 (S) 
Amoxicillin/Clavulanic acid 16 >9.6 >6.4 >9.6 6.4/0.4 (S) 
Ciprofloxacin 2 nt nt nt nt 
Trimethoprim/Sulfamethoxazole 76 nt nt nt nt 
Antibiotic 
Antibiotic 100% 
MIC 
Antibiotic 60% with R. 
delica  
 MIC/FIC (Effect) 
Antibiotic 40% with R. 
delica  MIC/FIC (Effect)   
Ampicillin 16 9.6/0.6 (I) 3.2/0.2 (S)   
Amoxicillin/Clavulanic acid 16 9.6/0.6 (I) 3.2/0.2 (S)   
Ciprofloxacin 2 nt nt   
Trimethoprim/Sulfamethoxazole 76 nt nt   
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Table 3. Effect of antibiotics individually and in combination with different mushroom extracts in Escherichia coli 2. 
MIC- Minimal inhibitory concentration (µg/mL); FIC- Fractional inhibitory concentration; (S)- Synergism; (I)- Indifference; nt- not tested. 
 
  
Antibiotic 
Antibiotic 100% 
MIC 
Antibiotic 60% with F. 
hepatica  MIC/FIC 
(Effect) 
Antibiotic 40% with F. 
hepatica MIC/FIC 
(Effect) 
  Antibiotic 60% with L. 
giganteus 
MIC/FIC (Effect) 
  Antibiotic 40% with  L. 
giganteus 
MIC/FIC (Effect) 
Ampicillin 16 nt nt >9.6 >6.4 
Amoxicillin/Clavulanic acid 16 nt nt nt nt 
Ciprofloxacin 2 nt nt >1.2 >0.8 
Trimethoprim/Sulfamethoxazole 76 nt nt >45.6 >30.4 
Antibiotic 
Antibiotic 100% 
MIC 
Antibiotic 60% with R. 
delica  
 MIC/FIC (Effect) 
Antibiotic 40% with R. 
delica  MIC/FIC (Effect)   
Ampicillin 16 4.8/0.3 (S) 1.6/ 0.1 (S)   
Amoxicillin/Clavulanic acid 16 nt nt   
Ciprofloxacin 2 0.6/0.3 (S) 0.2/0.1 (S)   
Trimethoprim/Sulfamethoxazole 76 45.6/0.6 (I) 15.2/0.2 (S)   
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Table 4. Effect of antibiotics individually and in combination with different mushroom extracts in Extended-spectrum beta-lactamase-producing 
(ESBL) Escherichia coli. 
MIC- Minimal inhibitory concentration (µg/mL); FIC- Fractional inhibitory concentration; (S)- Synergism; (I)- Indifference; nt- not tested. 
 
 
 
 
 
 
Antibiotic 
Antibiotic 100% 
MIC 
Antibiotic 60% with F. hepatica  
MIC/FIC (Effect) 
Antibiotic 40% with F. hepatica 
MIC/FIC (Effect) 
  Antibiotic 60% with L. giganteus 
MIC/FIC (Effect) 
  Antibiotic 40% with  L. 
giganteus 
MIC/FIC (Effect) 
Ampicillin 16 >9.6 >6.4 4.8/0.3 (S) 3.2/0.2 (S) 
Amoxicillin/Clavulanic acid 16 nt nt nt nt 
Ciprofloxacin 2 >1.2 >0.8 1.2/0.6 (I) 0.4/0.2 (S) 
Trimethoprim/Sulfamethoxazole  76 >45.6 >30.4 22.8/0.3 (S) 15.2/0.2 (S) 
Antibiotic Antibiotic 100% 
MIC 
Antibiotic 60% with R. delica  
 MIC/FIC (Effect) 
Antibiotic 40% with R. delica  
MIC/FIC (Effect)   
Ampicillin 16 4.8/0.3 (S) 1.6/0.1 (S)   
Amoxicillin/Clavulanic acid 16 nt nt   
Ciprofloxacin 2 0.6/0.3 (S) 0.2/0.1 (S)   
Trimethoprim/Sulfamethoxazole 76 22.8/0.3 (S) 7.6/0.1 (S)   
